SMN2 and proximal spinal muscular atrophy: In 2009, experiments in an animal model for spinal muscular atrophy (SMA), a rare neuromuscular disorder characterized by a loss of motor neurons and progressive muscle wasting, show that AONs that abrogate aberrant splicing of SMN2 are promising compounds for treating SMA [243].